Skip to main content

Profile: Ruiwen Zhang

Ruiwen Zhang
Ruiwen Zhang, M.D., Ph.D., D.A.B.T.
Professor of Pharmacology and Toxicology
Robert L. Boblitt Endowed Professor in Drug Discovery
Director of UH Center for Drug Discovery
Department of Pharmacological and Pharmaceutical Sciences
Science and Research Building 2
3455 Cullen Blvd., Room 114
Houston, TX 77204-5037

Education & Certifications

Ph.D. in Toxicology and Occupational Epidemiology, Shanghai Medical University (now Fudan University Shanghai Medical College)

M.D., Shanghai Medical University (now Fudan University Shanghai Medical College)

Post-Doc/Clinical Pharmacology Fellow, University of Alabama School of Medicine, Birmingham, AL

Diplomate, American Board of Toxicology, 1999-

Research Interests

Drug discovery and development; Molecular, biochemical, and clinical pharmacology and experimental therapeutics; Molecular cancer biology; Preclinical Pharmacology and Toxicology; Clinical Pharmacology and Clinical Trials; Pharmacogenetics/Pharmacogenomics; Gene regulation, gene silencing, and molecular targeting; Biotechnology and biopharmaceuticals; Cancer prevention and biomarkers; Nutrition and health

Research Support

Sponsor: NIH/NCI (R01 CA214019-01A1):
Title: Novel NFAT1-MDM2 inhibitor for Breast Cancer Therapy
PI: Ruiwen Zhang, M.D., Ph.D.
Funding Period: Funding Period: 9/4/17-8/31/2022
Total budget: $2,907,835

Sponsor: NIH/NCI (R01 CA 186662):
Title: Novel Small Molecule MDM2 Inhibitors for Pancreatic Cancer Therapy
PI: Ruiwen Zhang, M.D., Ph.D.
Funding Period: 4/1/14-2/29/2019
Total budget: $2,441,745

Sponsor: American Cancer Society
Title: Targeting MDM2 Oncogene for Breast Cancer Therapy
PI: Wei Wang, M.D., Ph.D.; Co-Investigator: Ruiwen Zhang, M.D., Ph.D.
Funding Period: 7/1/15-6/30/19
Total budget: $780,889

Honors and Awards

  • Fellow, American Association for the Advancement of Science (AAAS; 2009-)
  • Fellow, Molecular Medicine Society
  • Diplomate and Board Director (2009-2013), American Board of Toxicology
  • 2015 President’s Excellence in Research Award, Texas Tech University Health Science Center, TX
  • Organizing Committee Vice Chair, Keynote Speaker, Session I Chair: The First International Summit on Medical Research and Publication (FISOMRAP): October 17-18, 2015
  • Organizing Committee Chair, Conference Chair, Keynote Speaker, and Session II Chair: The 3rd International Conference on Biomedical Engineering and Pharmaceutical Sciences (ICBEPS2015): Nanjing, China. September 20-22, 2015
  • Organizing Committee and Session Chair, Keynote Speaker, International Conference "Bioinformatics and Biostatistics Applications in Cancer Genomics Research (BBACGR 2015)," Qatar University, Qatar National Research Fund, April 26-28, 2015, Doha, Qatar.
  • Special Oversea Expert Advisor, Chinese Association of Traditional Chinese Medicine (CATCM), Chapter of Basic Theory of Traditional Chinese Medicine; 2013-present
  • Outstanding Service Award, Society of Chinese Bioscientists in America (SCBA; 2010)
  • US FDA Advisory Committee Service Award (2008)
  • Honorary Professor – Southwest Hospital, Third Medical University, Chongqing, China, 2010-present; Shenyang Pharmaceutical University, Shenyang, China, 2008- present; Huazhong University of Science and Technology, Wuhan, China, 2007-present; Jiangsu University, Zhenjiang, China, 2007-present; The Third Military Medical University, China, 2006-present
  • Outstanding Speaker- The fifth Annual Meeting on Nutritional Sciences, Chinese Nutrition Society, 2006; Nantong University/Nantong Cancer Hospital/Institute, 2006-present
  • (Alabama) Governor Bob Reilly’s Business Mission; Delegate and Invited Speaker for Bio-forum Sponsored by Alabama State and Hubei Province, China, July 2006

Selected Publications

Dr. Zhang’s NCBI Bibliography link: http://www.ncbi.nlm.nih.gov/myncbi/browse/collection/40720220/?sort=date&direction=ascending

Xue B, Wang W, Qin JJ, Nijampatnam B, Murugesan S, Kozlovskaya V, Zhang R, Velu S, Kharlampieva E. Highly efficient delivery of potent anticancer iminoquinone derivative by multilayer hydrogel cubes. Acta Biomater. 2017; S1742-7061(17)30356-2.

Qin JJ, Wang W, Sarkar S, Zhang R. Oral Delivery of Anti-MDM2 Inhibitor SP141 with FcRn-targeted Nanoparticles to Treat Breast Cancer and Metastasis. J Controlled Release 2016;237: 101-14.

Qin JJ, Wang W, Voruganti S, Wang H, Zhang WD, Zhang R. Inhibiting NFAT1 for breast cancer therapy: New insights into the mechanism of action of MDM2 inhibitor JapA. Oncotarget 2015; 6(32): 33106-33119.

Wang W, Qin JJ, Voruganti S, Nag S, Zhou J, Zhang R. Polycomb Group (PcG) Proteins and Human Cancers: Multifaceted Functions and Therapeutic Implications. Med Res Rev 2015;35: 1220-67.

Voruganti S, Qin JJ, Sarkar S, Nag S, Walbi IA, Wang S, Zhao Y, Wang W, Zhang R. Oral nano-delivery of anticancer ginsenoside 25-OCH3-PPD, a natural inhibitor of the MDM2 oncogene: Nanoparticle preparation, characterization, in vitro and in vivo anti-prostate cancer activity, and mechanisms of action. Oncotarget 2015; 6(25): 21379-21394.

Voruganti S, Xu F, Qin JJ, Guo Y, Sarkar S, Gao M, Zheng Z, Wang MH, Zhou JW, Qian B, Zhang R, Wang W. RYBP predicts survival of patients with non-small cell lung cancer and regulates tumor cell growth and the response to chemotherapy. Cancer Letters 2015; 369:386-395

Wang W, Nag S, Zhang X, Wang MH, Wang H, Zhou J, Zhang R. Ribosomal Proteins and Human Diseases: Pathogenesis, Molecular Mechanisms, and Therapeutic Implications. Med Res Rev 2015;35:225-85.

Wang W, Qin JJ, Voruganti S, Srivenugopal KS, Nag S, Patil S, Sharma H, Wang MH, Buolamwini JK, Zhang R. A Pyrido[b]indole MDM2 Inhibitor, SP-141, Exerts Potent Therapeutic Effects in Breast Cancer Models. Nature Communications 2014;5:5086.

Qin JJ, Nag S, Wang W, Zhou J, Zhang WD, Wang H, Zhang R. NFAT as cancer target: Mission possible? BBA Reviews on Cancer 2014;1846:297-311.

Wang W, Qin JJ, Voruganti S, Wang MH, Sharma H, Patil S, Zhou J, Wang H, Mukhopadhyay D, Buolamwini JK, Zhang R. Identification of a New Class of MDM2 Inhibitor That Inhibits Growth of Orthotopic Pancreatic Tumors in Mice. Gastroenterology 2014;147:893-902.

Zhang X, Wang W, Wang H, Wang M-H, Xu W, Zhang R. Identification of ribosomal protein S25 (RPS25)-MDM2-p53 regulatory feedback loop. Oncogene 2013;32:2782-91.

Yao HP, Zhou YQ, Zhang R, Wang MH. MSP-RON Signaling in Cancer: Pathogenesis and Therapeutic Potential. Nature Reviews Cancer 2013; 13(7):466-481.

Zhang X, Zhang Z, Chen J, Li M, Wang W, Xu W, Wang H, Zhang R. Transcription factor NFAT1 activates the mdm2 oncogene independent of p53. J Biol Chem 2012;287:30468-76.

Xu H, Zhang Z, Li M, Zhang R. MDM2 promotes proteasomal degradation of p21Waf1 via a Conformation Change. J Biol Chem 2010; 285(24):18407-14.

Zhang X, Xu W, Qian H, Zhu W, Zhang R. Mesenchymal stem cells modified to express lentivirus-TNFα-Tumstatin45-132 inhibit the growth of prostate cancer. J Cell Mol Med. 2011; 15 (2): 433-444.

Wang W, Rayburn ER, Velu SE, Nadkarni DH, Murugesan S, Zhang R. In Vitro and In Vivo Anti-cancer Activity of Novel Synthetic Makaluvamine Analogs. Clin Cancer Res 2009;15:3511-8.

Wang W, Rayburn ER, Zhao Y, Wang H, Zhang R. Novel Ginsenosides 25-OH-PPD and 25-OCH3-PPD as Experimental Therapy for Pancreatic Cancer: Anticancer Activity and Mechanisms of Action. Cancer Lett 2009; 278(2):241-8.

Chen D, Zhang J, Li M, Rayburn ER, Wang H, Zhang R. RYBP (Ring-1 and YY1-binding protein) stabilizes p53 by modulating MDM2. EMBO Reports 2009;10:166-72.

Rayburn E, Zhang R. Antisense, RNAi, and gene silencing strategies for therapy: Mission possible or impossible? Drug Discov Today. 2008; 13(11-12):513-521.

Hou J, Wang D, Zhang R, Wang H. Experimental Therapy of Hepatoma with Artemisinin and Its Derivatives: In vitro and In vivo Activity, Chemosensitization, and Mechanisms of Action. Clin Cancer Res. 2008; 14(17):5519-5530.

Zhang Z, Zhang R. Proteasome activator PA28gamma regulates p53 by enhancing its MDM2-mediated degradation. EMBO Journal 2008;27:852-64.

Chen D, Zhang Z, Li M, Wang W, Li Y, Rayburn ER, Hill DL, Wang H, Zhang R. Ribosomal protein S7 as a novel modulator of p53-MDM2 interaction: binding to MDM2, stabilization of p53 protein, and activation of p53 function. Oncogene. 2007;26:5029-37.

Li M, Zhang Z, Hill D, Wang H, Zhang R. Curcumin, a Dietary Component, Has Anticancer, Chemosensitization, and Radiosensitization Effects by Down-regulating the MDM2 Oncogene through the PI3K/mTOR/ETS2 Pathway. Cancer Res. 2007;67:1988-96.

Wang H, Rayburn E, Wang W, Kandimalla ER, Agrawal S, Zhang R. Chemotherapy and chemosensitization of non-small cell lung cancer with a novel immunomodulatory oligonucleotide targeting Toll-like receptor 9. Mol Cancer Ther 2006; 5(6):1585-1592

Wang H, Rayburn E, Wang W, Kandimalla ER, Agrawal S, Zhang R. Immunomodulatory oligonucleotides as novel therapy for breast cancer: pharmacokinetics, in vitro and in vivo anti-cancer activity and potentiation of antibody therapy. Mol Cancer Ther 2006; 5(8): 2106-2114

Li M, Zhang Z, Hill D, Chen X, Wang H, Zhang R. Genistein, a dietary isoflavone, down-regulates MDM2 oncogene at both transcriptional and post-translational levels Cancer Research 2005;65:8200-8.

Zhang Z, Wang H, Li M, Rayburn E, Agrawal S, Zhang R. Stabilization of E2F1 protein by MDM2 through the E2F1 ubiquitination pathway. Oncogene 2005; 24(48):7238-7247.

Zhang Z, Wang H, Li M, Agrawal S, Chen X, Zhang R. MDM2 is a negative regulator of p21 WAF1/CIP1, independent of p53. J Biol Chem 2004; 279: 16000-16006.

Wang H, Li M, Rinehart JJ, Zhang R. Pretreatment with Dexamethasone Increases Anti-tumor Activity of Carboplatin and Gemcitabine in Mice Bearing Human Cancer Xenografts: In Vivo Activity, Pharmacokinetics and Clinical Implications for Cancer Chemotherapy. Clin Cancer Res. 2004; 10: 1633-1644.

Zhang Z, Wang H, Prasad G, Li M, Yu D, Bonner J, Agrawal S, Zhang R. Radiosensitization by antisense anti-MDM2 mixed-backbone oligonucleotide in in vitro and in vivo human cancer models. Clin Cancer Res. 2004; 10: 1263-1273.

Zhang Z, Li M, Wang H, Agrawal S, Zhang R. Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy. Proc Natl Acad Sci U S A. 2003;100:11636-41.

Kandimalla ER, Bhagat L, Wang D, Yu D, Zhu F, Tang J, Wang H, Huang H, Zhang R, Agrawal S. Divergent Synthetic Nucleotide Motif Recognition Pattern: Design and Development of Potent Immunomodulatory Oligodeoxyribonucleotide Agents with Distinct Cytokine Induction Profiles. Nucleic Acid Res. 2003; 31: 2393-2400.

Wang H, Nan L, Yu D, Agrawal S, Zhang R. Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: In vitro and in vivo activities and mechanisms. Clin Cancer Res 2001; 7: 3613-3624.

Wang H, Cai Q, Zeng X, Yu D, Agrawal S, Zhang R. Anti-tumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to RI subunit of protein kinase A after oral administration. Proc Natl Acad Sci USA 1999;96:13989-94.

Chen L, Agrawal S, Zhou W, Zhang R, Chen J. Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage. Proc Natl Acad Sci USA 1998;95:195-200.

Lu Z, Zhang R, Carpenter JT, and Diasio RB. Decreased dihydropyrimidine dehydrogenase activity in population of patients with breast cancer: implication for 5-fluorouracil-based chemotherapy. Clin Cancer Res. 1998; 4: 325-329.

Chen L, Agrawal S, Zhou W, Zhang R, Chen J. Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage. Proc Natl Acad Sci USA 1998; 95: 195-200.

Agrawal S, Jiang Z, Zhao Q, Shaw D, Cai Q, Roskey A, Channavajjala L, Saxinger C, Zhang R. Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: In vitro and in vivo studies. Proc Natl Acad Sci USA 1997;94:2620-5.

Zhang R, Yan J, Shahinian H, Amin G, Lu Z, Liu, T, Saag, MS, Jiang Z, Temsamani J, Martin RR, Schechter P, Agrawal S, Diasio RB. Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects. Clin Pharmacol Ther 1995; 58: 44-53.

Lu Z, Zhang R, Diasio RB. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 1993; 53: 5433-5438.

Zhang R, Lu Z, Liu T, Soong S-j, Diasio RB. Relationship between circadian-dependent toxicity of 5-fluorodeoxyuridine and circadian rhythms of pyrimidine enzymes. Possible relevance to fluoropyrimidine chemotherapy. Cancer Res 1993; 53: 2816-2822.

Lu Z, Zhang R, Diasio RB. Purification and characterization of dihydropyrimidine dehydrogenase from human liver. J Biol Chem 1992; 267 (24): 17102-17109.

Selected Book Chapter and Editorials

Zhang R. Traditional Chinese medicine: research and development, globalization, and regulation. Chin J Nat Med. 2017;15(1):1-3.

Zhang R. Preface: Scientific Premise and Rigors in Scientific Research, Peer Review, Editing and Publishing. Curr Cancer Drug Targets 2017; 17(1): 2.

Zhang R. Editorial: Artemisinin (Qing Hao Su), Nobel Prize, Anti-Malaria, and Beyond. Chin J Nat Med 2016; 14 (1):1-2.

Zhang R. Editorial: Cutting-Edge Publications Impacting Sciences: Beyond Natural Medicines. Chin J Nat Med 2015; 13 (3): 161-162.

Zhang R and Nag S: Nutraceuticals in Preventive Oncology: Chemical Biology and Translational Pharmaceutical Sciences in Special volume in book series in Advances in Pharmaceutical Sciences, Pharma-Nutrition; eds. Johan Garssen & Gert Folkerts, Springer, 2014; pp 304-345.

Zi X and Zhang R (Guest Editors): Hot Topic Issues: Anticancer Molecular Targets of Natural Products. Curr Cancer Drug Targets 2013. Vol. 13; Issue 5.

Zhang R. Genistein. Encyclopedia of Cancer. Ed. M. Schwab. Springer Berlin Heidelberg. Pp1533-1534; 2012

Zhang R, Buckoreelall K, Rayburn ER. Target Protein Database-p53; Current BioData Ltd, Middlesex House, London, UK; online 2008

Zhang R, Venn AR, Zhang Z, Rayburn ER. Target Protein Database-PA28gamma (PSME3); Current BioData Ltd, Middlesex House, London, UK; online 2008

Zhang R, Venn AR, Rayburn ER. Target Protein Database-PA28beta (PSME2)l; Current BioData Ltd, Middlesex House, London, UK; online 2008

Zhang R, Venn AR, Rayburn ER. Target Protein Database-PA28alpha (PSME1); Current BioData Ltd, Middlesex House, London, UK; online 2008

Zhang R, Buckoreelall K. Target Protein Database-XIAP; Current BioData Ltd, Middlesex House, London, UK; online 2008

Zhang R, Ezell SJ. Target Protein Database-MDM4/MDMx; Current BioData Ltd, Middlesex House, London, UK; online 2008

Zhang R, Rayburn ER. Target Protein Database-MDM2; Current BioData Ltd, Middlesex House, London, UK; online 2008

Zhang R and Rayburn E. Linkage between Toxicology of Drugs and Metabolism. In: Preclinical Safety Handbook: ADME and Biopharmaceutical Properties. Ed. Shayne C. Gad, John Wiley and Sons, Hoboken, NJ, 2008; pp 975-1008.

Zhang R and Wang H. Antisense Strategies for the Development of Novel Cancer Therapeutics. In: A.A. Adjei and J.K. Buolamwini, eds. Novel Anticancer Agents Strategies for Discovery and Clinical Testing. Elsevier Science, New York, NY, ISBN: 0-12-088561- 1. 2006; pp 193-206.

Selected Patents

1-Aryl-OR 1-heteroaryl-pyrido[b]indoles and uses thereof (U.S. patent application Serial No. 12/799,485; filed 4-26-2010; USPTO Publishing Date: 12-16-2010; #2010/0317667A1)

Marine alkaloid makaluvamines and derivatives thereof (U.S. patent application Serial No. #20100144779/514292; filed 2-23-2007; amended 2-23-2008; USPTO Publishing Date: 06/10/10; #US2010/0144779 A1)

Stabilization of p53 by Ribosomal Protein S7 (U.S. patent application Serial No. 60/889,110; filed 2-9-2007)

PA28y Regulation in Cells (U.S. patent application Serial No. 60/888,953; filed 2-9- 2007; WO 2008/121442 A2)

Novel Ginsenoside Compounds Compositions and Methods of Use (U.S. patent application Serial No. 60/870,250; filed 12-15-2006; WO 2008/076900 A1)

Methods and compositions related to increasing antitumor activity of chemotherapeutic agents. (U.S. patent application No. 60/567,766, filed on May 3, 2005).

Down-regulation of gene expression by colorectal administration of synthetic oligonucleotides. (US patent filed, No. 08/846, 427, 04/30/97; Patent Number EP 1 007098 B1)

Methods of down-regulating gene expression. (US Patent No. 6,936,593, 8/30/2005)

MDM2-Specific Antisense Oligonucleotides (US Patent No. 6,946,447, 9/20/2005)

Methods of down-regulating gene expression. (US Patent No. 6,608,035, 8/19/2003)

MDM2-Specific Antisense Oligonucleotides (US Patent No. 6,013,786, 1/11/2000)

Use of 2’-substituted oligonucleotides to down-regulate gene expression. European Patent Application Serial No. 95938213.6, filed 10/17/95, Case No. 178.0, Issued 12/15/99; Patent Number EP 0 788 366 B1.

A method for down-regulating gene expression. (US Patent No 5, 591,721, 1/7/1997)

DIHYDROPYRIMIDINE DEHYDROGENASE COMPOSITIONS AND METHODS OF USE- WO Patent 1,995,028,489, 1995

Selected Invited Lectures and Visiting Professorships (since 2013)

Rosalind Franklin University of Medicine and Science, Haim G. and Jane Graumann Nagirner Weinstein Symposium Series: Targeting NFAT1-MDM2 Pathway for Cancer Prevention & Therapy. Chicago, IL, September 18, 2017

The First Annual Meeting of Chongqing Medical Doctor Association for Nutrition Care: Keynote Speech: Translational Cancer Medicine & Nutritional Intervention. Chongqing, China, June 3, 2017
Shanghai Jiaotong University: Discovery and development of anti-MDM2 anticancer agents. Shanghai, China. December 14, 2016.

The Fourth Annual Conference of Chinese Society of Micro- & Nanoscience and Technology/ the 2016 International Conference of Nanobiology and Nanomedicine: Nano-delivery of Novel Anti-MDM2 Agents for Breast Cancer and Pancreatic Cancer Therapy. Fuzhou, China. December 7-10, 2016.

Zhejiang University: Targeting MDM2 Oncogene to Treat Human Cancers. Hangzhou, China. September 13, 2016.

Nanjing Medical University: Visiting Professor Lecture Series: Advanced Pharmacogenomics and Toxicogenomics. Nanjing, China. June 27-July 4, 2016.

The 8th International MDM2 Workshop: Invited Speech: Targeting MDM2 Oncogene for Cancer Prevention and Therapy: A 20-Year Learning Curve. New Orleans, LA. November 1-4, 2015.

Nanjing Medical University: Critical Thinking, Study Design, and Publishing Scientific Papers. Nanjing, China. October 23, 2015.

The First International Summit on Medical Research and Publication (FISOMRAP): Keynote Speech: Making a Competitive Grant Application: Innovation and Study Design. Wuhan, China. October 17-18, 2015.

China Pharmaceutical University: Keynote speech, Internationalization and Competitiveness of Chinese Scientific Publishing: Challenges and Opportunities. Nanjing, China. September 21, 2015.

The 3rd International Conference on Biomedical Engineering and Pharmaceutical Science (ICBEPS2015): Keynote speech, "Discovery and Development of MDM2 Inhibitors for Cancer Prevention and Therapy." Nanjing, China. September 20-22, 2015.

Chinese Association of Integrative Medicine: Keynote speech at the Sixth Symposium of Nutrition of CAIM, “Natural Products for Cancer Prevention and Therapy: Current Status, Mechanisms of Actions, and Future Directions”. Chongqing, China. September 18-12, 2015.

University of Oklahoma Health Sciences Center: Targeting MDM2 Oncogene for Cancer Prevention and Therapy: Oklahoma City, OH, August 21, 2015.

The 15th SCBA International Symposium: Targeting MDM2 Oncogene for Cancer Prevention and Therapy: A 20-year learning curve. Taipei, Taiwan, June 26-29, 2015.

Chinese Association of Traditional Chinese Medicines Shanghai Association of Infectious Diseases: Scientific Research Design and Reporting. Shanghai, China, May 8, 2015.

Tianjing Medical University: Targeting MDM2 Oncogene for Cancer Prevention and Therapy: Are We There Yet? Tianjing, China, May 6, 2015.

International Conference on Bioinformatics and Biostatistics in Cancer Genomics Research (BBACGR2015): Keynote Speech: Targeting MDM2 Oncogene for Cancer Prevention and Therapy: A 20-year Learning Curve. Doha, Qatar, April 26-28, 2015.

University of Tennessee Health Sciences Center: Targeting MDM2 Oncogene for Cancer Prevention and Therapy: A 20-year Learning Curve. Memphis, TN, January 12, 2015.

Chinese Pharmaceutical University: Making An English Biomedical Paper: Why, What, and How? December 15,2014.

Shanghai Jiao Tong University: Targeting MDM2 Oncogene for Cancer Prevention and Therapy: What We Have Learned Thus Far? Shanghai, China, October 28, 2014.

Nanjing Medical University: Study Design: Principles and Practice. Nanjing, China, October 27, 2014.

Nanjing Medical University: Targeting MDM2 Oncogene for Cancer Prevention and Therapy: A 20-year Learning Curve. Nanjing, China, October 27, 2014.

Nanjing Medical University: Scientific Publication in Making: Why, What, and How. Nanjing, China, October 26, 2014.

Chinese Pharmaceutical and Biomedical Publishing Forum/Nanjing Medical University: Keynote Speech: Publish or No Publish: Every Player’s Game. October 24-26, Nanjing, China, 2014.

North Dakoda State University: Targeting MDM2 Oncogene for Cancer Therapy: A Story Beyond P53, Fargo, ND, Sept 18, 2014.

University of South Alabama: Discovery and Development of MDM2 Inhibitors for Cancer Therapy: A 15-Year Learning Curve. Mobile, AL, August 26, 2014.

Chinese TCM Association for Infectious Diseases/Shanghai Division: Scientific Publication in Making: Why, What, and How? Shanghai, July 24, 2014.

Mayo Clinic: Targeting MDM2 Oncogene for Cancer Therapy and Prevention: Are We There yet? Rochester, MN, May 13, 2014.

The Second Military Medical University Changzheng Hospital: Advanced Scientific Communication and Writing. Shanghai, December 16, 2013.

The 3rd International Symposium for Emotion to Health and Disease with Intervention of Traditional Chinese Medicine and the 7th Academic Annual Conference for CATCM Chapter of Basic Theory of TCM: Keynote Speech: Translational Medicine, Traditional Medicine and International Collaboration. Dalian, China, August 22-25, 2013.

YanBian University: Translational Medicine: Concept and Practice. Yanji, Liaoning, China, July 6, 2013.

Tulane University Tulane Cancer Center: MDM2 Inhibitors for Cancer Therapy: Are We There yet? New Orleans, LA, May 9, 2013.

Published Abstracts and Presentations (since 2013)

Wang W, Zhang R. Targeting NFAT1-MDM2-p53 pathway for cancer therapy. The 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. Munich, Germany. November 29-December 2, 2016.

Wang MH, Feng L, Zhang R, Yao HP. Humanized anti-RON ADC for targeted cancer therapy: Commercial development toward investigational new drug clearance. TTUHSC SOP Research Days, Amarillo, TX, June 1-2, 2016.

Qin JJ, Wang W, Sarkar S, Zhang R. Oral Delivery of Anti-MDM2 Inhibitor SP141 with FcRn-targeted Nanoparticles to Treat Breast Cancer and Metastasis. TTUHSC SOP Research Days, Amarillo, TX, June 1-2, 2016.

Qin JJ, Sarkar S, Voruganti S, Wang W, Zhang R. Identification of Lineariifolianoid A as a novel dual NFAT1 and MDM2 inhibitor for cancer therapy. TTUHSC SOP Research Days, Amarillo, TX, June 1-2, 2016.

Qin JJ, Wang W, Sarkar S, Voruganti S, Zhang R. Inulanolide A as a new dual inhibitor of NFAT1-MDM2 pathway for breast cancer therapy. TTUHSC SOP Research Days, Amarillo, TX, June 1-2, 2016.

Wang W, Voruganti S, Qin JJ, Qian B, and Zhang R. RYBP predicts survival of patients with non-small cell lung cancer and sensitizes chemotherapy. Submitted to AACR-NCIEORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, MA, November 5-9, 2015.

Wang W, Zhang R. Involvement of RYBP in Growth and Response to Chemotherapy in Non-Small Cell Lung Cancer (#PB50). 15th SCBA International Symposium, Taiwan, June 26-29, 2015.

Zhang R. Targeting MDM2 Oncogene for Cancer Prevention and Therapy: A 20-Year Learning Curve. 15th SCBA International Symposium, Taiwan, June 26-29, 2015.

Wang W, Qin JJ, Voruganti S, Zhang R. Novel MDM2 Inhibitor for Breast Cancer Therapy: Where We Are and Where To Go? TTUHSC SOP Research Days, Amarillo, TX, June 11-12, 2015.

Qin JJ, Wang W, Cheng J, Voruganti S, Nag S, Fan J, Gao Q, Zhang R. RYBP as a novel target for cancer gene therapy and biomarker for prognosis. TTUHSC SOP Research Days, Amarillo, TX, June 11-12, 2015 (Best Poster Presentation-Post-Doc Associates).

Qin JJ, Wang W, Voruganti S, Zhang R. Identifying a novel natural product MDM2 inhibitor for breast cancer therapy. TTUHSC SOP Research Days, Amarillo, TX, June 11- 12, 2015 (Best Poster Presentation-Post-Doc Associates).

Voruganti S, Qin JJ, Wang W, Zhang R. Combination therapy with Adv-RYBP and chemotherapy in lung cancer. TTUHSC SOP Research Days, Amarillo, TX, June 11-12, 2015 (Best Poster Presentation-Sr. PhD Students).

Voruganti S, Qin JJ, Sarkar S, Nag S, Walbi IA, Wang S, Zhao Y, Wang W, Zhang R. Oral Nano-Delivery of Natural Anticancer Ginsenosides. TTUHSC SOP Research Days, Amarillo, TX, June 11-12, 2015 (Best Poster Presentation-Sr. PhD Students).

Ibrahim-Alobaide MA, Alobydi H, Abdelsalam AG, Zhang R, Sivenugopal KS. Characterization of a complex 5’-regulatory region of the cancer associated gene B4GALT1 and its comparison with the gene family. International Conference on Bioinformatics and Biostatistics, Applications in Genomics Research, Qatar, April 26-28, 2015.

Ibrahim-Alobaide MA, Abdelsalam AG, Alobydi H, Rasul KI, Zhang R, Sivenugopal KS. Structural features of alternative promoters of cisplatin resistance genes. International Conference on Bioinformatics and Biostatistics, Applications in Genomics Research, Qatar, April 26-28, 2015.

Zhang R. Targeting MDM2 oncogene for cancer therapy: A 20-year learning curve. International Conference on Bioinformatics and Biostatistics, Applications in Genomics Research, Qatar, April 26-28, 2015.

Alobaide MA, Alobydi H, Abdelsalam Abdelsalam A, Zhang R, Srivenugopal KS. Multiple alternative promoters and a long non-coding RNA constitute the complex regulatory region of the cancer and drug resistance associated gene B4GALT1. AACR annual meeting, Philadelphia, PA, April 18-22, 2015.

Voruganti S, Qin JJ, Wang W, Zhang R. The anticancer activity of Japonicone A is mediated by inhibiting NFAT1-MDM2 pathway. AACR annual meeting, Philadelphia, PA, April 18-22, 2015.

Qin JJ, Wang W, Voruganti S, Zhang R. A novel MDM2 inhibitor suppresses breast cancer growth and metastasis. AACR annual meeting, Philadelphia, PA, April 18-22, 2015.

Wang W, Chen J, Qin JJ, Voruganti S, Nag S, Fan J, Gai Q, Zhang R. VRYBP Expression Predicts Survival of Patients with Hepatocellular Carcinoma, and Regulates Response to Chemotherapy. AACR annual meeting, Philadelphia, PA, April 18-22, 2015.

Zhou S, Wang F, Xiang S, Wong E, Muhonen W, Fonkem E, Hsieh T-C, Li D, Zhang R, Shabb J, Wu M, Wu E. Identification and clinical prognosis of salinomycin binding targets in neuroblastoma (LB613). The FASEB Journal April 2014 vol. 28 no. 1 Supplement.

Sharma S, Feng L, Yao HP, Wang W, Zhang R, Wang MH, Therapeutic Activity of Antibody-Drug Conjugates Targeting RON and its Oncogenic Variant RONΔ160 for Potential Breast Cancer Therapy. TTUHSC SOP Research Days, Amarillo, TX, June 5-6, 2014.

Mostofa AGM, Feng L, Yao HP, Wang W, Zhang R, Wang MH, Anti-RON Antibody- Drug Conjugates in Combination with Chemotherapeutics as a Novel Therapeutic Strategy for Targeted Therapy of Pancreatic Cancers. TTUHSC SOP Research Days, Amarillo, TX, June 5-6, 2014.

Feng L, Yao HP, Wang W, Zhang R, Wang MH, Development of Anti-RON Antibody- Maytansinoid Conjugates (Anti-RON ADC) as a Potential Biotherapeutics for Targeted Colorectal Cancer Therapy. TTUHSC SOP Research Days, Amarillo, TX, June 5-6, 2014.

Feng L, Yao HP, Wang W, Sharma S, Zhang R, Wang MH, Preclinical evaluation of anti- RON antibody-drug maytansinoid conjugates (Anti-RON ADC) for targeted colorectal cacner therapy. Abstract #127341. ASCO annual meeting, Chicago, Illinois, May 30-June 3, 2014.

Feng L, Yao HP, Wang W, Sharma S, Zhang R, Wang MH, Anti-RON Antibody-Drug Maytansinoid Conjugates (Anti-RON ADC) as a Potential Biotherapeutics for Targeted Colorectal Cancer Therapy. AACR annual meeting, San Diego, CA, April 5-9, 2014.

Nag SA, Qin JJ, Wang MH, Wang W, Buolamwini JK, Zhang R. Ultra-performance liquid-chromatography for rapid analysis of SP-141, a novel experimental anticancer agent, and an initial pharmacokinetics and biodistribution study. Presented at the 2013 AAPS Annual Meeting and Exposition, San Antonio, TX, November 10-14, 2013

Qin JJ, Voruganti S, Wang MH, Zhang WD, Zhang R. Japonicone A as a Novel Anti- Breast Cancer Therapeutic Agent by Targeting the NFAT1-MDM2-p53 Pathway. Presented at the 2013 AAPS Annual Meeting and Exposition, San Antonio, TX, November 10-14, 2013

Voruganti S, Qin JJ, Wang W, Wang MH , Buolamwini JK, Zhang R. Novel Small Molecule MDM2 Inhibitors for Pancreatic Cancer Therapy. Presented at the 2013 AAPS Annual Meeting and Exposition, San Antonio, TX, November 10-14, 2013 (2013 AAPS Travel Award)

Zhang R. Keynote Speech: Translational Medicine, Traditional Medicine and International Collaboration. Proceeding of The 3rd International Symposium for Emotion to Health and Disease with Intervention of Traditional Chinese Medicine and the 7th Academic Annual Conference for CATCM Chapter of Basic Theory of TCM, Dalian, China, 2013; August 22-25; pp 2-6

Memberships

  • Fellow, American Association for the Advancement of Science (AAAS)
  • Fellow, Molecular Medicine Society
  • Member and Board Director (2009-2013), American Board of Toxicology
  • Member, American Association for Cancer Research (AACR); American Society for Biochemistry and Molecular Biology (ASBMB); American Association of Pharmaceutical Scientists (AAPS); American Society for Clinical Pharmacology and Therapeutics (ASCPT); American College of Toxicology (ACT); American Society for Microbiology (ASM); American Chemical Society (ACS); Drug Information Association (DIA); International Society for Nucleosides, Nucleotides, and Nucleic Acids (IS3NA)
  • Life Member, Cancer Division Officer, Society of Chinese Bioscientists in America (SCBA)

Editorial Appointments

  • Editor-in-Chief: Current Cancer Drug Targets, 2013-present; Medjaden Bioscience, 2005-present
  • Associate Editor-in-Chief: Journal of Nutritional Oncology, 2016-present; Chinese Journal of Natural Medicines, 2015-date
  • Associate Editor: Journal of Biomedical Research, 2015-date; Frontiers in Pharmacology, 2010-present; Therapeutics and Clinical Risk Management, 2004-present
  • Senior Editorial Board Member: International Journal of Biochemistry and Molecular Biology, 2009-present
  • Senior Advisory Board, Environmental Health Perspectives (Chinese Edition), 2010-present
  • Editorial Board Member: Pharmaceuticals & Drug Designing, 2014-present; Current Biotechnology, 2014-present; Genes and Diseases, 2014-present; Journal of Biomedical Research, 2013-present; Journal of Bioequivalence & Bioavailability, 2013-present; Drug Intoxication & Detoxification: Novel Approaches, 2012-present; Drug Discoveries and Therapeutics, 2011-present; The Open Biomarker, 2008-present; Advances in Pharmacological Sciences, 2008-present; The Open Cancer Journal, 2006-present; Scientific Journals International, 2005-present; Current Medicinal Chemistry-Anti-Cancer Agents, 2005-present; Recent Patent Reviews on Anti -Cancer Drug Discovery, 2005-present; Journal of Biological Sciences, 2004-present; Current Medicinal Chemistry, 2004-present; Medicinal Chemistry, 2004-present; Medicinal Chemistry Reviews -Online, 2003-present; Letters in Drug Design and Discovery, 2002-present
  • Reviewer, Acta Anaesthesiologica Scandinavica; Acta Pharmacologica Sinica; Acta Physiologiae Plantarum; Biochemical Pharmacology; Biochim Biophys Acta; Biological Procedure-online; Biomaterials; Bioorganic and Medicinal; Chemistry; Breast Cancer Research; Breast Cancer Research and Treatment; British Journal of Pharmacology; British Journal of Nutrition; Cancer; Cancer Biology & Therapy; Cancer Epidemiology, Biomarkers and Prevention; Cancer Letters; Cancer Research; Cancer Treatment Reviews; Carcinogenesis; Cell Cycle; Cell Proliferation; Cell Research; Clinical Cancer Research; Clinical Drug Investigation; Clinical Pharmacology and Therapeutics; Current Pharmaceutical Design; Current Pharmacogenomics; Cutaneous and Ocular Toxicology; Environmental Health Perspective; Environmental Pollution; Environmental Toxicology; European Journal of Medicinal Chemistry; Evidence-Based Complementary and Alternative Medicine; Expert Opinion on Drug Discovery; Expert Opinion on Therapeutic Patents; Expert Opinion on Therapeutics; Expert Reviews in Molecular Medicine; Food and Chemical Toxicology; Free Radical Biology and Medicine; Gynecological Oncology; Hepatology; Indian Journal of Medical Research; Investigational New Drugs; International Journal of Biological Sciences; International Journal of Biological Markers; International Journal of Cancer; International Journal of Medical Sciences; Journal of Biomedical Material Research (Part A); Journal of Biomolecular Screening; Journal of Biotechnology; Journal of Cellular Physiology; Journal of Cellular and Molecular Medicine; Journal of Chemical Information and Modeling; Journal of Clinical Oncology; Journal of Clinical Pharmacy and Therapeutics; Journal of Controlled Release; Journal of Ethnopharmacology; Journal of Gastroenterology and Hepatology; Journal of Medicinal Chemistry; Journal of Molecular Medicine; Journal of Nutritional Biochemistry; Journal of Liposome Research; Journal of Pharmaceutical Science; Journal of Pharmacology and Experimental Therapeutics; Liver International; Leukemia Research; Medicinal Chemistry Communications; Molecular Cancer; Molecular Cancer Research; Molecular Cancer Therapeutics; Molecular Carcinogenesis; Molecular and Cellular Biochemistry; Molecular Medicine; Molecular Nutrition and Food Research; Molecular Pharmacology; Neural Plasticity; Natural Product Research; Neoplasia; Neuroimmunomodulation; Nucleic Acids Research; Nutrition Journal; Oligonucleotides; Oncogene; Oncotarget; Pharmaceutical Development and Technology; Pharmaceutical Research; Pharmacologica Sinica; Phytotherapy Research; Planta Medica; PlosOne; Rapid Communications in Mass Spectrometry; Science Translational Medicine; Scientific Journals International; Southern Medical Journal; Therapeutic Delivery; Toxicological Sciences; Toxicology Letters; Toxicology Reports; Tumor Biology